Efficacy and Safety of Esketamine Nasal Spray in Patients with Treatment-Resistant Depression Who Completed a Second Induction Period: Analysis of the Ongoing SUSTAIN-3 Study
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- Umfang
-
Online-Ressource, 1 online resource.
- Sprache
-
Englisch
- Erschienen in
-
Efficacy and Safety of Esketamine Nasal Spray in Patients with Treatment-Resistant Depression Who Completed a Second Induction Period: Analysis of the Ongoing SUSTAIN-3 Study ; volume:37 ; number:8 ; day:9 ; month:8 ; year:2023 ; pages:715-723 ; date:8.2023
CNS drugs ; 37, Heft 8 (9.8.2023), 715-723, 8.2023
- Urheber
-
Castro, Meredith
Wilkinson, Samuel T.
Al Jurdi, Rayan K.
Petrillo, Mary Pat
Zaki, Naim
Borentain, Stephane
Fu, Dong Jing
Turkoz, Ibrahim
Sun, Liping
Brown, Brianne
Cabrera, Patricia
- Beteiligte Personen und Organisationen
-
SpringerLink (Online service)
- DOI
-
10.1007/s40263-023-01026-3
- URN
-
urn:nbn:de:101:1-2023110414261160623355
- Rechteinformation
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
14.08.2025, 10:48 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Castro, Meredith
- Wilkinson, Samuel T.
- Al Jurdi, Rayan K.
- Petrillo, Mary Pat
- Zaki, Naim
- Borentain, Stephane
- Fu, Dong Jing
- Turkoz, Ibrahim
- Sun, Liping
- Brown, Brianne
- Cabrera, Patricia
- SpringerLink (Online service)
Ähnliche Objekte (12)
Personalized use of ketamine and esketamine for treatment-resistant depression
Cost-Utility Analysis of Esketamine for Patients with Treatment-Resistant Depression in Italy
Oral esketamine for treatment-resistant depression: rationale and design of a randomized controlled trial
Cost-utility analysis of esketamine and electroconvulsive therapy in adults with treatment-resistant depression
Cardiac Safety of Esketamine Nasal Spray in Treatment-Resistant Depression: Results from the Clinical Development Program
Correction to: Oral esketamine for treatment-resistant depression: rationale and design of a randomized controlled trial
Use of intranasal esketamine in a girl with treatment-resistant depression and autism spectrum disorders : a case report
Phenomenology and therapeutic potential of patient experiences during oral esketamine treatment for treatment-resistant depression: an interpretative phenomenological study
Management of treatment-resistant depression with esketamine nasal spray: clinical questions for daily practice in Gulf Cooperation Council countries
The Lighthouse completed
Efficacy and safety of esketamine nasal spray by sex in patients with treatment-resistant depression: findings from short-term randomized, controlled trials
Treatment Patterns, Acute Healthcare Resource Use, and Costs of Patients with Treatment-Resistant Depression Completing Induction Phase of Esketamine in the United States
Personalized use of ketamine and esketamine for treatment-resistant depression
Cost-Utility Analysis of Esketamine for Patients with Treatment-Resistant Depression in Italy
Oral esketamine for treatment-resistant depression: rationale and design of a randomized controlled trial
Cost-utility analysis of esketamine and electroconvulsive therapy in adults with treatment-resistant depression
Cardiac Safety of Esketamine Nasal Spray in Treatment-Resistant Depression: Results from the Clinical Development Program
Correction to: Oral esketamine for treatment-resistant depression: rationale and design of a randomized controlled trial
Use of intranasal esketamine in a girl with treatment-resistant depression and autism spectrum disorders : a case report
Phenomenology and therapeutic potential of patient experiences during oral esketamine treatment for treatment-resistant depression: an interpretative phenomenological study
Management of treatment-resistant depression with esketamine nasal spray: clinical questions for daily practice in Gulf Cooperation Council countries
The Lighthouse completed
Efficacy and safety of esketamine nasal spray by sex in patients with treatment-resistant depression: findings from short-term randomized, controlled trials
Treatment Patterns, Acute Healthcare Resource Use, and Costs of Patients with Treatment-Resistant Depression Completing Induction Phase of Esketamine in the United States
Personalized use of ketamine and esketamine for treatment-resistant depression
Cost-Utility Analysis of Esketamine for Patients with Treatment-Resistant Depression in Italy
Oral esketamine for treatment-resistant depression: rationale and design of a randomized controlled trial
Cost-utility analysis of esketamine and electroconvulsive therapy in adults with treatment-resistant depression
Cardiac Safety of Esketamine Nasal Spray in Treatment-Resistant Depression: Results from the Clinical Development Program
Correction to: Oral esketamine for treatment-resistant depression: rationale and design of a randomized controlled trial
Use of intranasal esketamine in a girl with treatment-resistant depression and autism spectrum disorders : a case report
Phenomenology and therapeutic potential of patient experiences during oral esketamine treatment for treatment-resistant depression: an interpretative phenomenological study
Management of treatment-resistant depression with esketamine nasal spray: clinical questions for daily practice in Gulf Cooperation Council countries
The Lighthouse completed
Efficacy and safety of esketamine nasal spray by sex in patients with treatment-resistant depression: findings from short-term randomized, controlled trials